Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life

(2010) Smita S. Joshi et al.   CANCER

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

(2010) Mario E. Lacouture et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Epidermal Growth Factor Receptor Antagonist-Induced Skin Rash: Results of a Survey among German Oncologists

(2010) Jessica C. Hassel et al.   ONKOLOGIE

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

(2010) Mario E. Lacouture et al.   SUPPORTIVE CARE IN CANCER

Evidence-Based Treatment Options for the Management of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors

(2009) Eng Hooi Tan et al.   ANNALS OF PHARMACOTHERAPY

Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors

(2009) A. Osio et al.   BRITISH JOURNAL OF DERMATOLOGY

Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy

(2009) Ajay Tejwani et al.   CANCER

MANAGEMENT OF SKIN RASH DURING EGFR-TARGETED MONOCLONAL ANTIBODY TREATMENT FOR GASTRO INTESTINAL MALIGNANCIES: CANADIAN RECOMMENDATIONS

(2009) Barb Melosky et al.   Current Oncology

Cetuximab Therapy of Metastasizing Cutaneous Squamous Cell Carcinoma in a Patient with Severe Recessive Dystrophic Epidermolysis Bullosa

(2009) Andreas W. Arnold et al.   DERMATOLOGY

Skin toxicities of targeted therapies

(2009) Siegfried Segaert et al.   EUROPEAN JOURNAL OF CANCER

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

(2009) Andrew N. Hughes et al.   JOURNAL OF CLINICAL ONCOLOGY

A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption

(2009) Alon Scope et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia

(2009) T Eames et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy

(2009) R. E. Eilers et al.   JNCI-Journal of the National Cancer Institute

Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147

(2009) Aminah Jatoi et al.   ONCOLOGY

Skin toxicities associated with epidermal growth factor receptor inhibitors

(2009) Tianhong Li et al.   Targeted Oncology

Scarring Alopecia Associated With Use of the Epidermal Growth Factor Receptor Inhibitor Gefitinib

(2008) Jeffrey C. Donovan et al.   ARCHIVES OF DERMATOLOGY

Analysis of dermatologic events in patients with cancer treated with lapatinib

(2008) M. E. Lacouture et al.   BREAST CANCER RESEARCH AND TREATMENT

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes

(2008) Aminah Jatoi et al.   CANCER

Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Paul Wheatley-Price et al.   JOURNAL OF CLINICAL ONCOLOGY

Is There Room for Improvement in Adverse Event Reporting in the Era of Targeted Therapies?

(2008) M. Edgerly et al.   JNCI-Journal of the National Cancer Institute

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2

(2008) Q. Ryan et al.   ONCOLOGIST

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab

(2008) Bernhard Berger et al.   Radiation Oncology